Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8NDM7
UPID:
CFA43_HUMAN
Alternative names:
WD repeat-containing protein 96
Alternative UPACC:
Q8NDM7; Q8N9Z8; Q8NE17; Q9H085; Q9H5W3
Background:
Cilia- and flagella-associated protein 43, also known as WD repeat-containing protein 96, plays a crucial role in the organization and function of sperm flagellum axoneme. This protein is pivotal for the proper beating frequency of motile cilia in the respiratory tract, suggesting its significant role in both reproductive and respiratory health.
Therapeutic significance:
The protein is linked to Spermatogenic failure 19, characterized by defects in spermatogenesis leading to infertility, and Hydrocephalus, normal pressure, 1, marked by progressive neurological decline. Targeting this protein could offer novel therapeutic avenues for treating these conditions.